{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T14:16:17Z","timestamp":1783174577118,"version":"3.54.6"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972632"],"award-info":[{"award-number":["81972632"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373160"],"award-info":[{"award-number":["82373160"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2024YFC3506600"],"award-info":[{"award-number":["2024YFC3506600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002367","name":"Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002367","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019958","name":"Shanghai Advanced Research Institute, Chinese Academy of Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","award":["2025ZD1803301"],"award-info":[{"award-number":["2025ZD1803301"]}],"id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Cell Research"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.yexcr.2026.115044","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:21:18Z","timestamp":1776871278000},"page":"115044","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chemogenetic screen identifies EphA2 as a synthetic lethal vulnerability in MYC-driven triple-negative breast cancer"],"prefix":"10.1016","volume":"460","author":[{"given":"Meng","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3268-1122","authenticated-orcid":false,"given":"Zhe","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.yexcr.2026.115044_bib1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s41573-025-01143-2","article-title":"MYC in cancer: from undruggable target to clinical trials","volume":"24","author":"Whitfield","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115044_bib2","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3390\/ph18070978","article-title":"Beyond the limit: MYC mediates tumor immune escape","volume":"18","author":"Hong","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"16","key":"10.1016\/j.yexcr.2026.115044_bib3","doi-asserted-by":"crossref","first-page":"13296","DOI":"10.1021\/jacs.4c18144","article-title":"Proteomimetic strategy for the modulation of intrinsically disordered protein MYC","volume":"147","author":"Nguyen","year":"2025","journal-title":"J. Am. Chem. Soc."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115044_bib4","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.62347\/RTVX8866","article-title":"Exploiting replication stress for synthetic lethality in MYC-driven cancers","volume":"15","author":"Zhang","year":"2025","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.yexcr.2026.115044_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2025.101290","article-title":"The role of synthetic lethality in overcoming cancer therapy resistance: emerging paradigm and recent advances","volume":"83","author":"Xiong","year":"2025","journal-title":"Drug Resist. Updates"},{"issue":"3","key":"10.1016\/j.yexcr.2026.115044_bib6","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.tips.2020.11.014","article-title":"Capitalizing on synthetic lethality of MYC to treat cancer in the digital age","volume":"42","author":"Thng","year":"2021","journal-title":"Trends Pharmacol. Sci."},{"issue":"6","key":"10.1016\/j.yexcr.2026.115044_bib7","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1158\/0008-5472.CAN-21-1707","article-title":"Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells","volume":"82","author":"Sun","year":"2022","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115044_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2025.115327","article-title":"Targeting both the enzymatic and non-enzymatic functions of DHODH as a therapeutic vulnerability in c-Myc-driven cancer","volume":"44","author":"Zhang","year":"2025","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib9","doi-asserted-by":"crossref","first-page":"7582","DOI":"10.1038\/s41467-025-62615-y","article-title":"Genome-wide in vivo CRISPR screens identify GATOR1 complex as a tumor suppressor in Myc-driven lymphoma","volume":"16","author":"Potts","year":"2025","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib10","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1038\/s41467-024-46572-6","article-title":"Therapeutic targeting nudix hydrolase 1 creates a MYC-driven metabolic vulnerability","volume":"15","author":"Ye","year":"2024","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib11","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41467-024-45128-y","article-title":"Nuclear to cytoplasmic transport is a druggable dependency in MYC-driven hepatocellular carcinoma","volume":"15","author":"Deutzmann","year":"2024","journal-title":"Nat. Commun."},{"issue":"24","key":"10.1016\/j.yexcr.2026.115044_bib12","doi-asserted-by":"crossref","first-page":"4015","DOI":"10.1158\/0008-5472.CAN-22-2948","article-title":"Topoisomerase 1 inhibition in MYC-driven cancer promotes aberrant R-Loop accumulation to induce synthetic lethality","volume":"83","author":"Lin","year":"2023","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115044_bib13","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.ccell.2022.10.009","article-title":"Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma","volume":"40","author":"Gwynne","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.yexcr.2026.115044_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2025.217803","article-title":"MLCK inhibition induces synthetic lethality in MYC-driven cancer","volume":"625","author":"Sun","year":"2025","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s13045-022-01341-0","article-title":"Recent advances in therapeutic strategies for triple-negative breast cancer","volume":"15","author":"Li","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.yexcr.2026.115044_bib16","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.semcancer.2020.06.005","article-title":"Pathology of triple negative breast cancer","volume":"72","author":"Borri","year":"2021","journal-title":"Semin. Cancer Biol."},{"issue":"11","key":"10.1016\/j.yexcr.2026.115044_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/nm.4213","article-title":"PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression","volume":"22","author":"Horiuchi","year":"2016","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115044_bib18","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1084\/jem.20111512","article-title":"MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition","volume":"209","author":"Horiuchi","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.yexcr.2026.115044_bib19","article-title":"Alanine catabolism as a targetable vulnerability for MYC-driven liver cancer","author":"Montoya","year":"2025","journal-title":"bioRxiv"},{"issue":"24","key":"10.1016\/j.yexcr.2026.115044_bib20","doi-asserted-by":"crossref","first-page":"9545","DOI":"10.1073\/pnas.1121119109","article-title":"Functional genomics identifies therapeutic targets for MYC-driven cancer","volume":"109","author":"Toyoshima","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.yexcr.2026.115044_bib21","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3390\/pharmaceutics16050625","article-title":"Unlocking potential and limits of kinase inhibitors: the highway to enhanced cancer targeted therapy","volume":"16","author":"Musumeci","year":"2024","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.yexcr.2026.115044_bib22","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1021\/acs.jmedchem.1c00963","article-title":"Small molecule kinase inhibitor drugs (1995-2021): medical indication, pharmacology, and synthesis","volume":"65","author":"Ayala-Aguilera","year":"2022","journal-title":"J. Med. Chem."},{"issue":"33","key":"10.1016\/j.yexcr.2026.115044_bib23","doi-asserted-by":"crossref","first-page":"13130","DOI":"10.1039\/D4SC01088D","article-title":"The prospect of substrate-based kinase inhibitors to improve target selectivity and overcome drug resistance","volume":"15","author":"Biswas","year":"2024","journal-title":"Chem. Sci."},{"issue":"3","key":"10.1016\/j.yexcr.2026.115044_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0248355","article-title":"A high-content screen identifies the vulnerability of MYC-overexpressing cells to dimethylfasudil","volume":"16","author":"Zhang","year":"2021","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.yexcr.2026.115044_bib25","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/nm1606","article-title":"Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC","volume":"13","author":"Goga","year":"2007","journal-title":"Nat. Med."},{"issue":"2","key":"10.1016\/j.yexcr.2026.115044_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/2159-8290.CD-14-0552","article-title":"Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map","volume":"5","author":"Martins","year":"2015","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.yexcr.2026.115044_bib27","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.190136","article-title":"Oncogenic MYC amplifies mitotic perturbations","volume":"9","author":"Littler","year":"2019","journal-title":"Open Biol."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115044_bib28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/nm.4107","article-title":"A MYC-Aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer","volume":"22","author":"Dauch","year":"2016","journal-title":"Nat. Med."},{"issue":"31","key":"10.1016\/j.yexcr.2026.115044_bib29","doi-asserted-by":"crossref","first-page":"13836","DOI":"10.1073\/pnas.1008366107","article-title":"Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase","volume":"107","author":"Yang","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12 Pt 1","key":"10.1016\/j.yexcr.2026.115044_bib30","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1158\/1535-7163.MCT-07-0444","article-title":"PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer","volume":"6","author":"Carpinelli","year":"2007","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib31","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1158\/1535-7163.MCT-10-0574","article-title":"ENMD-2076 is an orally active kinase inhibitor with antiangiogenic and antiproliferative mechanisms of action","volume":"10","author":"Fletcher","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib32","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13058-018-1014-y","article-title":"A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer","volume":"20","author":"Diamond","year":"2018","journal-title":"Breast Cancer Res."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115044_bib33","doi-asserted-by":"crossref","first-page":"3973","DOI":"10.1021\/jm901870q","article-title":"Discovery of GSK1070916, a potent and selective inhibitor of Aurora B\/C kinase","volume":"53","author":"Adams","year":"2010","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115044_bib34","doi-asserted-by":"crossref","first-page":"742","DOI":"10.14740\/jocmr2295w","article-title":"Aurora kinases and potential medical applications of Aurora kinase inhibitors: a review","volume":"7","author":"Gavriilidis","year":"2015","journal-title":"J. Clin. Med. Res."},{"issue":"7","key":"10.1016\/j.yexcr.2026.115044_bib35","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/emmm.201202341","article-title":"CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer","volume":"5","author":"Cepeda","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"24","key":"10.1016\/j.yexcr.2026.115044_bib36","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1038\/onc.2014.257","article-title":"VEGF drives cancer-initiating stem cells through VEGFR-2\/Stat3 signaling to upregulate Myc and Sox2","volume":"34","author":"Zhao","year":"2015","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.yexcr.2026.115044_bib37","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.ccell.2020.01.001","article-title":"Direct phosphorylation and stabilization of MYC by Aurora B Kinase promote T-cell leukemogenesis","volume":"37","author":"Jiang","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.yexcr.2026.115044_bib38","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s43018-020-00171-8","article-title":"Combined inhibition of Aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma","volume":"2","author":"Roeschert","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.yexcr.2026.115044_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2024.112661","article-title":"Co-targeting CDK 4\/6 and C-MYC\/STAT3\/CCND1 axis and inhibition of tumorigenesis and epithelial-mesenchymal-transition in triple negative breast cancer by Pt(II) complexes bearing NH(3) as trans-co-ligand","volume":"259","author":"Lv","year":"2024","journal-title":"J. Inorg. Biochem."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115044_bib40","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1248\/bpb.b17-00446","article-title":"Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression","volume":"40","author":"Zhou","year":"2017","journal-title":"Biol. Pharm. Bull."},{"issue":"5","key":"10.1016\/j.yexcr.2026.115044_bib41","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1172\/JCI72522","article-title":"Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC","volume":"124","author":"Amato","year":"2014","journal-title":"J. Clin. Investig."},{"issue":"15","key":"10.1016\/j.yexcr.2026.115044_bib42","doi-asserted-by":"crossref","first-page":"4467","DOI":"10.1016\/j.bmcl.2009.05.029","article-title":"Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors","volume":"19","author":"Choi","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"10","key":"10.1016\/j.yexcr.2026.115044_bib43","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605366","article-title":"Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors","volume":"101","author":"Kumar","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.yexcr.2026.115044_bib44","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/nrd2380","article-title":"Molecular basis for sunitinib efficacy and future clinical development","volume":"6","author":"Faivre","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"issue":"24","key":"10.1016\/j.yexcr.2026.115044_bib45","doi-asserted-by":"crossref","first-page":"15541","DOI":"10.1021\/acs.jmedchem.0c01346","article-title":"Discovery of Pamiparib (BGB-290), a potent and selective poly (ADP-ribose) polymerase (PARP) inhibitor in clinical development","volume":"63","author":"Wang","year":"2020","journal-title":"J. Med. Chem."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib46","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ccr.2009.04.009","article-title":"EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt","volume":"16","author":"Miao","year":"2009","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.cellsig.2010.09.004","article-title":"Crosstalk of the EphA2 receptor with a serine\/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells","volume":"23","author":"Yang","year":"2011","journal-title":"Cell. Signal."},{"issue":"6743","key":"10.1016\/j.yexcr.2026.115044_bib48","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/22780","article-title":"Creation of human tumour cells with defined genetic elements","volume":"400","author":"Hahn","year":"1999","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.yexcr.2026.115044_bib49","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1128\/MCB.22.7.2111-2123.2002","article-title":"Enumeration of the simian virus 40 early region elements necessary for human cell transformation","volume":"22","author":"Hahn","year":"2002","journal-title":"Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib50","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1101\/gad.828901","article-title":"Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells","volume":"15","author":"Elenbaas","year":"2001","journal-title":"Genes Dev."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115044_bib51","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd2662","article-title":"Targeting apoptosis: selected anticancer strategies","volume":"7","author":"Storey","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"issue":"40","key":"10.1016\/j.yexcr.2026.115044_bib52","doi-asserted-by":"crossref","first-page":"5620","DOI":"10.1038\/onc.2017.170","article-title":"Targeting EphA2 impairs cell cycle progression and growth of basal-like\/triple-negative breast cancers","volume":"36","author":"Song","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.yexcr.2026.115044_bib53","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s12935-025-03826-7","article-title":"EphrinA2 promotes glioma cell migration and invasion through EphA2 and FAK","volume":"25","author":"Hirai","year":"2025","journal-title":"Cancer Cell Int."},{"issue":"4","key":"10.1016\/j.yexcr.2026.115044_bib54","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1158\/1535-7163.MCT-18-0539","article-title":"EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer","volume":"18","author":"Martini","year":"2019","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.yexcr.2026.115044_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252212191","article-title":"EphA2 in cancer: molecular complexity and therapeutic opportunities","volume":"25","author":"Toracchio","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.yexcr.2026.115044_bib56","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1038\/s41419-018-1164-y","article-title":"EPH receptor A2 governs a feedback loop that activates Wnt\/\u03b2-catenin signaling in gastric cancer","volume":"9","author":"Peng","year":"2018","journal-title":"Cell Death Dis."}],"container-title":["Experimental Cell Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014482726001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T13:21:11Z","timestamp":1783171271000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014482726001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0014482726001618"],"URL":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.115044","relation":{},"ISSN":["0014-4827"],"issn-type":[{"value":"0014-4827","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemogenetic screen identifies EphA2 as a synthetic lethal vulnerability in MYC-driven triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Experimental Cell Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexcr.2026.115044","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115044"}}